IE 11 is not supported. For an optimal experience visit our site on another browser.

BioNeutral Chief Scientist Andrew Kielbania is Featured With Bob Salter on Radio WFAN

/ Source: GlobeNewswire

NEW YORK, Sept. 7, 2010 (GLOBE NEWSWIRE) -- Chief Scientist Andrew Kielbania PhD of BioNeutral Group, Inc. (OTCBB:BONU), a specialty chemical technology-based life science company, talked with WFAN Radio host Bob Salter in a detailed interview Sunday, September 5, about the growing need for improved infection control in health care facilities and BioNeutral's Ygiene™ disinfectant, which is under submission to the Environmental Protection Agency for use as a disinfectant.

Kielbania was interviewed Sunday by Bob Salter, the radio host of the public affairs program on WFAN. WFAN is heard throughout the New York tri-state area and worldwide on   To hear the broadcast, go to:

Salter noted that each year more than 1.7 million Americans will get a drug-resistant infection from a hospital and 100,000 of them will die.

The Center for Disease Control reported May 12, 2010, that there are at least 100,000 deaths in the United States annually from hospital-related infections.

"There is an unmet need in hospitals because there are not many alternatives to the alcohol-based sanitizers currently in use," Kielbania said.

Kielbania said BioNeutral's patent-pending, environmentally friendly antimicrobial Ygiene™ kills bacteria, viruses and even spores virtually on contact, even "Superbugs" like C-dificil and MRSA.

BioNeutral's chief scientist also reported that the hand sanitizers hospitals frequently use give a "false sense of security" because the "Superbugs" are resistant to many of them. 

Kielbania noted that many of these infections are also found in nursing homes, rehabilitation facilities, doctors' and dentists' offices and other kinds of healthcare facilities since they use the same type of cleaning protocols as hospitals.

BioNeutral Ygiene was submitted to the Environmental Protection Agency for registration approval in August 2010, following positive independent results in the extensive Good Laboratory Practice (GLP) testing required for acceptance for EPA review. Ygiene has been approved for sale as a disinfectant in Germany, United Kingdom, France and Sweden.

Kielbania also reported that BioNeutral has a complete platform of Ogiene™ based products, which are comprised of toxic gas and odor eliminators plus a full range of specialized and multi-purpose cleaners.    

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene™ and Ogiene™, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace.  BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene™ brand have been submitted to the EPA for approval for sale in the United States and has already been approved for sale in Germany and is permitted to be sold in the UK, France and Sweden. Ogiene-based AutoNeutral™ Odor Eliminator is currently commercially available in the United States.  For more information, see

Forward-Looking Statements

BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene™ and are not yet available for sale in the United States.

CONTACT: Stern & Co. PR/Media Relations: Richard Stern 212-888-0044 Hayden IR Investor Relations: Brett Maas 646/536-7331 BioNeutral Group Inc. Stephen J. Browand, President and CEO 973-286-2899